Eli Lilly’s Taltz (ixekizumab) Receives Health Canada’s Approval for Active Ankylosing Spondylitis

 Eli Lilly’s Taltz (ixekizumab) Receives Health Canada’s Approval for Active Ankylosing Spondylitis

Eli Lilly’s Taltz (ixekizumab) Receives Health Canada’s Approval for Active Ankylosing Spondylitis

Shots:

  • The approval follows two P-III studies (COAST V & COAST W) assessing Taltz (q4w) vs PBO in 657 patients with active AS who are bDMARD-naïve & intolerant to TNF inhibitors respectively
  • The P-III studies result:  improvement in 1EPs i.e. achievement of ASAS40 @16wks. (48% & 25% vs 18% & 13%); improvement in 2EPs (64% & 48% vs 40% & 30%); safety profile is consistent with psoriasis patients
  • Taltz is a mAb targeting IL-17A thus inhibiting its interaction with IL-17 receptor and hinders the release of pro-inflammatory cytokines and chemokines and has received Health Canada’s approval for PsO & PsA in 2016 and 2018 respectively

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: WFAE

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post